Demerol Meperidine Market Highlights

The global demerol meperidine market is accounted to register a CAGR of 5.51% during the forecast period and is estimated to reach USD 1.8 Billion by 2032.

The market for the opioid analgesic demerol meperidine is altered by changing pain management guidelines and laws. It encounters difficulties because of worries about opioids, which forces a balance between medical necessity and potential hazards.

Key Players

MRFR recognizes the following companies as the key players in the global Demerol Meperidine market— Actavis PLC, Sun Pharmaceuticals, Sanofi, Boehringer Ingelheim, Pfizer, Inc., Janssen Pharmaceuticals, Inc., Egalet Corporation, Mallinckrodt Pharmaceuticals, Purdue Pharma, Endo Pharmaceuticals Inc. and others

Segment Analysis

The global demerol meperidine market has been segmented based product type and application.

On the basis of product type, the market is segmented into parenteral and tablets. The parenteral segment dominated the market in 2022. Rapid action is essential for effectively treating acute and severe pain, and parenteral intravenous (IV) injection offers this. Additionally, parenteral administration is frequently utilized in hospitals and clinics where medical experts can guarantee precise dosing and careful observation of the patient's response.  

Based on application, the global demerol meperidine market has been segmented into pain relief, anesthesia, cough suppression, diarrhea suppression and de-addiction. The pain relief category generated the most income in 2022. The prevalence of acute and chronic painful conditions, such as post-operative pain, injury-related pain, cancer-related pain, and chronic illnesses, is what is driving the demand for effective pain management medications.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Demerol Meperidine Market Research Report

Regional Analysis

The global demerol meperidine market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Demerol Meperidine market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Demerol Meperidine market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Demerol Meperidine market comprises of Middle East, Africa, and Latin America.

The North America demerol meperidine market dominated this market in 2022 (45.80%). One of the greatest rates of chronic pain syndromes are found in North America. The American Pain Society estimates that 50 million adults in the US deal with chronic pain. Meperidine is a popular analgesic for people with chronic pain.

Moreover, the second-largest market share for demerol meperidine is held by Europe. One of the main factors propelling the meperidine market in Europe is the increase in surgical procedures. According to the European Society of Anesthesiology, 20 million surgical procedures would likely be performed in Europe in 2020. A common anesthetic used in numerous surgical procedures is meperidine.

Additionally, the Asia-Pacific demerol meperidine market is expected to grow at the fastest CAGR from 2023 to 2032. Rising healthcare awareness and an increased emphasis on pain management are driving demand in the Asia Pacific region for strong painkillers like Demerol. As people grow more knowledgeable about their healthcare alternatives, there may be a rise in the demand for effective painkillers.

Furthermore, the rest of the world's demerol meperidine market is divided into the Middle East, Africa, and Latin America. The Demerol (Meperidine) market in Latin America faces evolving pain management practices and regulatory changes. Balancing accessibility for medical needs with opioid concerns remains a challenge, impacting the availability and usage of this opioid analgesic.

Key Findings of the Study

• The global demerol meperidine market is expected to reach USD 1.8 Billion by 2032, at a CAGR of 5.51% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market In Asia Pacific, demand for potent painkillers like Demerol is being driven by rising healthcare awareness and a greater focus on pain treatment. The demand for appropriate painkillers may increase as people become more aware of their healthcare options.


• Based on product type, the parenteral segment was attributed to holding the largest market in 2022.


• Actavis PLC, Sun Pharmaceuticals, Sanofi, Boehringer Ingelheim, Pfizer, Inc., Janssen Pharmaceuticals, Inc., Egalet Corporation, Mallinckrodt Pharmaceuticals, Purdue Pharma, Endo Pharmaceuticals Inc. and others